bioMérieux SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013280286
EUR
89.40
-0.25 (-0.28%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

125.08 k

Shareholding (Dec 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Flat results in Jun 25

  • INTEREST(HY) At EUR 7.5 MM has Grown at 134.38%
  • ROCE(HY) Lowest at 9.69%
  • EPS(Q) Lowest at EUR 1.35
2

With ROE of 12.50%, it has a Very Expensive valuation with a 2.84 Price to Book Value

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 10,670 Million ()

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.06

stock-summary
Return on Equity

12.36%

stock-summary
Price to Book

2.60

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.73%
0%
-18.73%
6 Months
-20.88%
0%
-20.88%
1 Year
-23.52%
0%
-23.52%
2 Years
-11.66%
0%
-11.66%
3 Years
-11.13%
0%
-11.13%
4 Years
-6.03%
0%
-6.03%
5 Years
-18.13%
0%
-18.13%

bioMérieux SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.46%
EBIT Growth (5y)
10.49%
EBIT to Interest (avg)
67.90
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.92
Tax Ratio
22.70%
Dividend Payout Ratio
29.09%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
18.06%
ROE (avg)
13.41%

Valuation key factors

Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.84
EV to EBIT
17.71
EV to EBITDA
11.62
EV to Capital Employed
2.84
EV to Sales
2.71
PEG Ratio
0.99
Dividend Yield
NA
ROCE (Latest)
16.01%
ROE (Latest)
12.50%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by bioMérieux SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.31% vs 2.38% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 31.69% vs -26.72% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,979.90",
          "val2": "3,674.70",
          "chgp": "8.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "893.30",
          "val2": "795.10",
          "chgp": "12.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "16.00",
          "val2": "4.40",
          "chgp": "263.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.40",
          "val2": "-125.90",
          "chgp": "84.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "425.10",
          "val2": "322.80",
          "chgp": "31.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "148.50%",
          "val2": "145.80%",
          "chgp": "0.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
3,979.90
3,674.70
8.31%
Operating Profit (PBDIT) excl Other Income
893.30
795.10
12.35%
Interest
16.00
4.40
263.64%
Exceptional Items
-19.40
-125.90
84.59%
Consolidate Net Profit
425.10
322.80
31.69%
Operating Profit Margin (Excl OI)
148.50%
145.80%
0.27%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.31% vs 2.38% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 31.69% vs -26.72% in Dec 2023

stock-summaryCompany CV
About bioMérieux SA stock-summary
stock-summary
bioMérieux SA
Pharmaceuticals & Biotechnology
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Company Coordinates stock-summary
Company Details
376 chemin de l'Orme , MARCY-L ETOILE None : 69280
stock-summary
Tel: 33 4 7887200033 4 78872237
stock-summary
Registrar Details